Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3842]

Engineered immune cells show promise against brain metastases in preclinical study

Engineered immune cells show promise against brain metastases in preclinical study

ASCO GU 2026: Belzutifan plus pembrolizumab post-surgery helps ccRCC patients at high risk for relapse stay cancer-free longer

ASCO GU 2026: Belzutifan plus pembrolizumab post-surgery helps ccRCC patients at high risk for relapse stay cancer...

ASCO GU 2026: Combo targeting blood vessel growth controls ccRCC better than single agent

ASCO GU 2026: Combo targeting blood vessel growth controls ccRCC better than single agent

Fifteen-year results from SWOG S0016 trial suggest follicular lymphoma is curable

Fifteen-year results from SWOG S0016 trial suggest follicular lymphoma is curable

ASCO GU 2026: Enfortumab vedotin pembrolizumab combo may reduce risk of recurrence for some MIBC cases

ASCO GU 2026: Enfortumab vedotin pembrolizumab combo may reduce risk of recurrence for some MIBC cases

FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

Discovery could improve immune checkpoint inhibitor safety

Discovery could improve immune checkpoint inhibitor safety

Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer

Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer

Existing drug unlocks immunotherapy potential against rare liver cancer

Existing drug unlocks immunotherapy potential against rare liver cancer

Unraveling the mystery of why some cancer treatments stop working

Unraveling the mystery of why some cancer treatments stop working

More from ecancer